Published: Jan. 1, 2024
Language: Английский
Biomedicines, Journal Year: 2024, Volume and Issue: 12(1), P. 187 - 187
Published: Jan. 15, 2024
In recent years, the field of drug delivery has witnessed remarkable progress, driven by quest for more effective and precise therapeutic interventions. Among myriad strategies employed, integration aptamers as targeting moieties stimuli-responsive systems emerged a promising avenue, particularly in context anticancer therapy. This review explores cutting-edge advancements targeted drug-delivery systems, focusing on platforms enhanced spatial aptamer-based we delve into versatile applications aptamers, examining their conjugation with gold, silica, carbon materials. The synergistic interplay between these materials is discussed, emphasizing potential achieving delivery. Additionally, explore an emphasis Tumor microenvironment-responsive nanoparticles are elucidated, capacity to exploit dynamic conditions within cancerous tissues controlled release detailed. External strategies, including ultrasound-mediated, photo-responsive, magnetic-guided examined role effects. integrates diverse approaches precision medicine, showcasing revolutionize
Language: Английский
Citations
19
International Journal of Pharmaceutics, Journal Year: 2024, Volume and Issue: 665, P. 124687 - 124687
Published: Sept. 10, 2024
Language: Английский
Citations
9
Journal of Drug Delivery Science and Technology, Journal Year: 2025, Volume and Issue: unknown, P. 106614 - 106614
Published: Jan. 1, 2025
Language: Английский
Citations
1
ACS Measurement Science Au, Journal Year: 2024, Volume and Issue: 5(1), P. 31 - 55
Published: Nov. 15, 2024
Cancer immunotherapy is an innovative way of treating cancer by stimulating individual cells to overcome cancer. Widespread biomedical studies were carried out with the aim exploring therapeutics, and this review spotlights some mechanisms in which it was developed, namely immune checkpoint inhibitors (E.G PD-1/PD-L1, CTLA-4), adoptive cell therapy (e.g., CAR T-cell therapy), vaccines. Although has shown clinical benefit a number types, including melanoma non-small-cell lung cancer, several challenges have dampened enthusiasm for approach, from differing patient response rates toxicities. Nanotechnology drug delivery systems must play role overcoming same. enables increased specificity controlled release, improved solubility bioavailability, can treat tumor specifically, localized at disease site decreases systemic toxicity. The also features advances construction lipid-based, polymeric, inorganic nanoparticles that improve stability allow cotherapeutic agents. Nanotechnology-based be used alone or combination assist improving response, gaining access microenvironment, biological barriers. Thus, nano-DDS both safe effective preclinical studies, ongoing trials they are capable increasing therapeutic index anticancer drugs. Lastly, discusses current regulatory issues advancing these technologies highlights importance further research devise appropriate methodology efficient functionalization nanotechnology individualized solutions treatment.
Language: Английский
Citations
5
Cancers, Journal Year: 2023, Volume and Issue: 15(21), P. 5300 - 5300
Published: Nov. 6, 2023
Ovarian cancer (OC) is the most common lethal gynecologic cause of death in women worldwide, with a high mortality rate and increasing incidence. Despite advancements treatment, OC patients still die from their disease due to late-stage diagnosis, lack effective diagnostic methods, relapses. Aptamers, synthetic, short single-stranded oligonucleotides, have emerged as promising anticancer therapeutics. Their ability selectively bind target molecules, including cancer-related proteins receptors, has revolutionized drug discovery biomarker identification. Aptamers offer unique insights into molecular pathways involved development progression. Moreover, they show immense potential delivery systems, enabling targeted therapeutic agents cells while minimizing off-target effects reducing systemic toxicity. In context OC, integration aptamers non-coding RNAs (ncRNAs) presents an opportunity for precise efficient gene targeting. Additionally, conjugation nanoparticles allows accurate ncRNAs specific cells, tissues, or organs. this review, we will summarize use challenges associated alone aptamer–ncRNA conjugates, nanoparticles, multivalent aptamer-based therapeutics treatment OC.
Language: Английский
Citations
13
Translational Oncology, Journal Year: 2024, Volume and Issue: 46, P. 102023 - 102023
Published: June 8, 2024
Medulloblastoma is a type of brain cancer that primarily affects children. While chemotherapy has been shown to be effective in treating medulloblastoma, the development resistance remains challenge. One potential therapeutic approach selectively inhibit inducible transcription factor called STAT3, which known play crucial role survival and growth tumor cells. The activation STAT3 linked progression various cancers, including medulloblastoma. Inhibition sensitize medulloblastoma cells chemotherapy, leading improved treatment outcomes. Different approaches inhibition have developed, small-molecule inhibitors RNA interference. Preclinical studies efficacy clinical trials are currently ongoing evaluate their safety effectiveness patients with solid tumors, In addition, researchers also exploring ways optimize use combination identify biomarkers can predict will help develop personalized strategies. This review highlights selective as novel for suggests further research into could lead outcomes aggressive cancer.
Language: Английский
Citations
4
International Journal of Nanomedicine, Journal Year: 2025, Volume and Issue: Volume 20, P. 3493 - 3525
Published: March 1, 2025
Human serum albumin (HSA) has emerged as a promising carrier for nanodrug delivery, offering unique structural properties that can be engineered to overcome key challenges in cancer treatment, especially resistance chemotherapy. This review focuses on the cellular uptake of albumin-based nanoparticles and modifications enhance their ability bypass mechanisms, particularly multidrug type 1 (MDR1), by improving targeting cells. In our approach, we integrate chemical albumin, its interactions with cells, surface delivery systems enable those related MDR1, precisely target receptors cells improve treatment efficacy. We discuss while well-established such gp60 gp18/30 are crucial transcytosis, biology remains underexplored, limiting translational potential. Additionally, explore potential emerging targets, cluster differentiation 44 (CD44), (CD36) transferrin receptor TfR1, well advantages using dimeric forms (dHSA) further resistant Drawing from clinical examples, including success albumin-bound paclitaxel (Abraxane) new formulations like Pazenir Fyarro (for Sirolimus), identify gaps current knowledge propose strategies optimize systems. conclusion, nanoparticles, when tailored appropriate modifications, have By enhancing albumin's efficiently deliver therapeutic agents, these carriers represent approach addressing one oncology's most persistent challenges, substantial outcomes.
Language: Английский
Citations
0
Journal of Drug Delivery Science and Technology, Journal Year: 2024, Volume and Issue: 100, P. 106107 - 106107
Published: Aug. 25, 2024
Language: Английский
Citations
3
Biomaterials Advances, Journal Year: 2025, Volume and Issue: 171, P. 214235 - 214235
Published: Feb. 15, 2025
Language: Английский
Citations
0
Frontiers in Immunology, Journal Year: 2025, Volume and Issue: 16
Published: Feb. 17, 2025
Aptamer-based immunotherapy can be a new hope for treating solid tumors with personalized and specific approaches toward cancer therapies. Aptamers are small synthetic single-stranded nucleic acids that may bring in paradigm shift tumors. These highly selective drugs applied cellular immunotherapy, cytokine modulation, immune checkpoint suppression. This review provides an overview of the recent advances aptamer-based technologies key clinical trials involving AON-D21 AM003. potently active regulation tumor targeting. However, aptamer stability bioavailability seriously compromised by issues relating to renal clearance rapid degradation through nucleases. The latter reviewed here along novel improvements, some which involve chemical modifications greatly enhance prolong circulation time; exemplary such PEGylation, cholesterol conjugation, synthesis circular acids. regulatory aspect is also crucial. For example, addition strategies prevent drug-drug interactions (DDIs) remediation medications, this paper underscores need risk assessment, particularly because immunogenicity organ failure. use aptamers expanded development SOMAmers, X-aptamers, bioinformatics. To make major part treatment, future research should concentrate more on resolving existing expanding their beneficial uses.
Language: Английский
Citations
0